Clinical trials
MDS (Myelodysplastic Syndrome) clinical trials
Below are recruiting mds (myelodysplastic syndrome) clinical trials, each written for real people, not researchers. We’re tracking 228 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT00801489RecruitingPhase 2
New treatment for AML or high-risk MDS using combination chemo
This trial tests a combination treatment (chemo drugs plus a growth-factor medicine) for people newly diagnosed with acute myeloid leukemia (AML) or certain high-risk myelodysplastic syndromes (MDS). It may help by targeting cancer cells in the blood and bone marrow and improving remission chances.
Houston, TexasAges 18 years+ - NCT01624805RecruitingPhase 2
Immunosuppressant treatment to help low blood counts in some bone marrow disorders
This trial tests a group of immune-suppressing medicines (with steroids and growth-factor injections) for people with aplastic anemia or certain low-risk myelodysplastic syndromes. The goal is to improve bone marrow function and reduce problems caused by low blood counts, such as fatigue, infections, or bleeding.
Houston, TexasAges 18 years+ - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT02727803RecruitingPhase 2
Personalized natural killer cell therapy for blood cancers
This trial tests a customized immune-cell treatment (NK cells) for certain blood cancers to try to control or eliminate cancer cells. You may qualify if your cancer has come back, did not fully respond, or has higher risk features.
Houston, TexasAges 15–80 - NCT07400341RecruitingPhase 2
Romiplostim vs rhTPO for platelet recovery after transplant
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
Suzhou, JiangsuAges 18–65 - NCT07532824RecruitingPhase 1/Phase 2
Proton Radiation and Stem Cell Transplant for High-Risk Blood Cancers
This trial tests a new type of radiation therapy (proton-based) combined with a stem cell transplant from a donor to treat advanced forms of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). The goal is to improve survival in patients with aggressive or hard-to-treat disease.
PragueAges 18–65 - NCT05674539Enrolling by invitationPhase 3
Less intense transplant regimen for AML or MDS patients
This trial tests whether a less intense chemotherapy and transplant plan can work for adults with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are getting a stem cell transplant. It may help reduce transplant-related harm, especially in people considered higher risk due to age or other health factors.
Wuhan, HubeiAges 18 years+ - NCT03128034RecruitingPhase 1/Phase 2
Astatine-211 treatment before stem cell transplant for high-risk blood cancers
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
Seattle, WashingtonAges 18–75 - NCT05796570RecruitingPhase 2
Decitabine plus filgrastim to prevent relapse after transplant
This trial tests whether giving decitabine with filgrastim soon after a stem cell transplant can be done safely and may help prevent the leukemia or related cancer from coming back. It is aimed at children and young adults with AML, MDS, or related myeloid cancers.
Boston, MassachusettsAges 1–39 - NCT05924074Recruiting
Study of ferroptosis therapy in blood disorders with SF3B1 mutation
This study looks at ferroptosis (a type of cell stress that can affect blood-forming cells) in people with certain blood disorders linked to an SF3B1 gene change. It may help researchers understand whether targeting this pathway could improve outcomes.
PessacAges 18 years+ - NCT06569095Recruiting
Study of stem cells in myelodysplastic syndrome
This study looks at special stem cells in the blood or bone marrow of people with myelodysplastic syndromes (MDS). It aims to better predict how the disease might progress and help guide treatment decisions.
BeijingAges 15–70 - NCT06918834RecruitingPhase 2
Immediate vs bridging transplant for high-risk MDS
This trial compares getting a stem cell transplant right away versus getting other treatments first before transplant for people with high-risk myelodysplastic syndrome (MDS), a bone marrow disorder. It aims to see which approach leads to better outcomes.
Beijin, Beijing MunicipalityAges 18 years+ - NCT07347171RecruitingPhase 1
Testing CG009301 for blood cancers that returned or didn't respond
This trial tests a new drug called CG009301 for people with blood cancers that have come back or haven't responded to standard treatments. The goal is to see if the drug is safe and works against these cancers.
NanchangAges 18–75 - NCT07607418RecruitingPhase 2
Ivosidenib maintenance therapy for IDH1-mutated blood cancers
This trial tests whether taking ivosidenib as a maintenance drug (to keep the cancer in remission) works better than standard care for patients with IDH1-mutated AML or high-risk MDS who cannot undergo a bone marrow transplant. Ivosidenib is a targeted drug that blocks a specific mutation found in your cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03896269RecruitingPhase 1
CPX-351 for high-risk MDS or CMML that came back
This Phase 1 trial studies CPX-351, a cancer medicine, in people with high-risk myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) whose disease relapsed or did not respond to prior treatment. It may help shrink or control the leukemia and improve blood counts in patients who cannot or do not want a stem cell transplant.
Houston, TexasAges 18 years+ - NCT05805605RecruitingPhase 2
Low-intensity stem cell transplant with donor cells and blood-protection
This Phase 2 study tests a low-intensity bone marrow/stem cell transplant using a matched donor plus two medicines to help prevent the donor cells from attacking you. It aims to treat certain blood cancers—especially when standard treatment has not fully worked or when you are in remission but at higher risk.
Minneapolis, MinnesotaAges Up to 75 years - NCT05902416Recruiting
Testing haplo transplant for older adults with leukemia or MDS
This study looks at using a “half-matched” stem cell transplant (haploidentical transplant) in adults around your age with acute leukemia or MDS. It may help people who cannot find a fully matched donor, but are still eligible for this type of transplant.
Beijing, Beijing MunicipalityAges 55–70 - NCT06270771Recruiting
Using a wearable ring to monitor MDS patients at home
This study tests if people with MDS can comfortably wear the OURA ring (a smart ring) at home to track their health. The goal is to see if this is a useful way to monitor symptoms and well-being between doctor visits.
Toronto, OntarioAges 18 years+ - NCT06892223RecruitingPhase 2
Anti-NKG2A antibody for leukemia or MDS after half-matched transplant
This trial tests a drug that targets NKG2A, a protein that may help prevent cancer cells from hiding from the immune system. It is for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or related conditions who have already received a half-matched stem cell transplant (haploidentical transplant) with a specific anti-rejection drug plan.
Genova, GENOVAAges 18–99 - NCT06303193RecruitingPhase 1/Phase 2
Testing a kinase inhibitor drug for MDS and MDS/MPN in adults and teens
This trial tests a drug called pacritinib in people with myelodysplastic syndromes (MDS) or MDS/myeloproliferative neoplasms (MDS/MPN). The drug targets several proteins that may help control the disease, especially for those who have not responded to other treatments.
Bethesda, MarylandAges 12–120 - NCT06196203RecruitingPhase 2
Study of AK117 with Azacitidine for High-Risk MDS
This trial tests a new drug, AK117, combined with azacitidine for people newly diagnosed with high-risk myelodysplastic syndromes (MDS), a blood disorder. The goal is to see if the combination can help improve outcomes.
Los Angeles, CaliforniaAges 18 years+ - NCT04243785RecruitingPhase 1
Testing BTX-A51 for hard-to-treat AML or high-risk MDS
This Phase 1 study tests BTX-A51 in adults with relapsed or refractory acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). It’s designed to see if the treatment can be given safely and to learn how it works in people whose standard treatments have not helped or are no longer an option.
Duarte, CaliforniaAges 18 years+
Hear when a new MDS (Myelodysplastic Syndrome) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for mds (myelodysplastic syndrome)?
- Yes. Clin2 currently lists 228 recruiting mds (myelodysplastic syndrome) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a mds (myelodysplastic syndrome) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a mds (myelodysplastic syndrome) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.